AACR 2024 | SYNC-T combination immunotherapy in mCRPC

George Prendergast, PhD, Lankenau Institute for Medical Research (LIMR), Wynnewood, PA, gives an overview of findings from a pilot study of SYNC-T therapy in solid tumors that have undergone cryolysis. SYNC-T therapy was shown to produce very promising responses in patients with metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.